|3140/2||ETT Activator (0.25M)|
|3145/6||ETT Activator (0.5M)|
|3160/2||BTT Activator (0.3M)|
|4010||Cap Mix A: THF/lutidine/acetic anhydride (8:1:1)|
|4012||Cap Mix A: THF/acetic anhydride (9:1)|
|4050||Diluent/Anhydrous Wash: Acetonitrile, anhydrous|
|4110||Cap Mix A: THF/pyridine/acetic anhydride (8:1:1)|
|4120||Cap Mix B: 10% Methylimidazole in THF|
|4122||Cap Mix B: 10% Methylimidazole in THF/pyridine (8:1)|
|4132||Oxidiser: 0.02M Iodine in THF/pyridine/water (89.6:0.4:10)|
|4140||Deblock Mix: 3% TCA in DCM|
|4230||Oxidiser: 0.1M Iodine in THF/pyridine/water (78:20:2)|
|4330||Oxidiser: 0.02M Iodine in THF/pyridine/water (7:2:1)|
|Various||SynBase™ CPG Solid Supports|
Physical & Dilution Data
Dilution volumes (in ml) are for 0.1M solutions in dry acetonitrile (4050). Adjust accordingly for other concentrations. For µmol pack sizes, products should be diluted as 100µmol/ml to achieve 0.1M, regardless of molecular weight.
The Synthesis Cycle
Conventional automated solid-phase oligonucleotide synthesis is performed in a small synthesis ‘column’ into which the solid support (typically CPG or polystyrene) has been packed. A solid support is selected functionalised with the first base (or modification) required at the 3’-end of the oligonucleotide. The synthesis cycle is then carried out on the instrument as per the manufacturer’s instructions. All steps are carried out under positive argon pressure, principally to prevent exposure of the reactive PIII species to air. Timings of the steps will vary with instrument type, but will in general consist of the following:
The 5’-DMTr group of the 5’-terminal base is removed by brief exposure to a ‘deblocking’ acid, typically 3% trichloroacetic acid (TCA) in dichloromethane (DCM) (4140), but also 3% dichloroacetic acid (DCA) in DCM (4040) or 5% DCA in toluene (4500). The spectrophotometric assay of the resultant trityl cation can be measured to monitor the efficiency of the synthesis reaction.
Activation & Coupling
To add the next base to the deblocked 5’-OH, the appropriate phosphoramidite is first activated. This is typically achieved using either a tetrazole-type (0.3M BTT (3160/3162), 0.25M ETT (3140/3142) or 0.5M ETT (3145/3146)) or an imidazole-type (0.25M DCI; please note we no longer offer this product). The activated species is then reacted with the 5’-OH to give a trivalent phosphite triester. Typically the coupling reaction uses a 20-fold molar excess of activator and a 5-fold molar excess of phosphoramidite with respect to the starting scale of the synthesis column. Coupling times vary depending on the phosphoramidite being used. Standard base coupling is typically 30s but modifiers tend to need much longer (typically 5-10min).
While the coupling reaction is very efficient (generally 98-99%), a very small percentage of 5’-OH remains unreacted. These reactive groups are capped, typically by acetylation, to prevent reaction during subsequent couplings leading to deletion sequences. The acetylation is achieved using a mixture of acetic anhydride (Cap Mix A (4110/4012)) and N-methylimidazole (Cap Mix B (4120/4122)) in the presence of base (typically pyridine or lutidine). There is no noticeable difference in the choice of base.
The unstable trivalent phosphite triester is oxidised to the stable pentavalent phosphotriester, by use of either 0.1M or 0.02M iodine in THF/pyridine/water (4230/4330/4132). The oxidation step completes a single base cycle of the oligonucleotide synthesis (although for longer oligos a second capping step is often carried out after the oxidation).
For the synthesis of phosphorothioate oligos, the oxidation step is replaced by a sulphurisation. However, the capping step must be carried out after the sulphurisation, not before.
Cleavage & Deprotection
After synthesis, the oligonucelotide is cleaved from the support and deprotected. Traditionally, this is a two-step process; cleave then deprotect. However, today it is not uncommon for this to be carried out in one step. This is particularly true where gas phase deprotections are employed using gaseous anhydrous ammonia. In this case, the fully deprotected oligonucleotide is eluted from the support either with water, ready for quantification, or buffer, ready for purification. This method is particularly useful for high throughput synthesis. In general the deprotection conditions are determined by the modification type incorporated into the oligonucleotide. They can also be determined by the nucleobase protection used to synthesise the oligo backbone.
Standard DNA bases protected with traditional groups (Bz-dA (2003), Bz-dC (2004) and iBu-dG (2002)) are generally deprotected using ammonium hydroxide solution. This deprotection is generally slow and not compatible with all modifications. The introduction of Ac-dC (2034) and dmf-dG (2030), and the corresponding RNA bases, allow much faster deprotection using AMA. Additionally these allowed deprotection of oligonucleotides containing sensitive modifcations such as TAMRA where deprotection with tbutylamine/MeOH/water (1:1:2) is required. However, there was still the need for even milder deprotection. This became possible with Pac-protected amidites where it is possible to deprotect the nucleobases with potassium carbonate solution.
The use of the monomer set Bz-dA, Ac-dC and dmf-dG allows deprotection in AMA (10min at 65°C) provided any modifications present are compatible with this.
At this point, oligos are generally purified and ‘desalted’.
DMT ON Synthesis
For various reasons (e.g. to aid purification), an oligonucleotide is synthesised “DMT ON” and the final dimethoxytrityl group only removed after or during purification. To achieve this there is no treatment with deblock after the final phosphoramidite addition. The oligo is cleaved and deprotected as required. If the DMTr group is retained during purification this can be removed by treatment with acid (80% acetic acid in water).
Storage & Stability
Standard phosphoramidites are refrigerated at 2 to 8°C. Stability in anhydrous acetonitrile solution is 2-3 days.